Public-registry site landscape for NCT01928537, a Myelodysplastic Syndromes study sponsored by Traws Pharma, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT01928537 (registry record) |
| Sponsor | Traws Pharma, Inc. |
| Condition(s) | Myelodysplastic Syndromes; Refractory Anemia With Excess Blasts; Chronic Myelomonocytic Leukemia; Cytopenia |
| Phase | PHASE3 |
| Listed sites | 35 |
| Site countries | United States, Australia, Denmark, France, Germany, Italy, Spain, Sweden |
Eichor generates a preliminary site-risk snapshot for NCT01928537 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →